Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor

Clinical and Experimental Metastasis

Volumn 15, Issue 2, 1997, Pages 184-195

  An, Zili ^a   Wang, Xiaoen ^a   Willmott, Neville ^b   Chander, Surinder K ^b   Tickle, Simon ^b   Docherty, Andrew J P ^b   Mountain, Andrew ^b   Millican, Andrew T ^b   Morphy, Richard ^b   Porter, John R ^b   Epemolu, R Ola ^b   Kubota, Tetsuro ^c   Moossa, A R ^d   Hoffman, Robert M ^a,d,e  

^a ANTICANCER INC   (United States)

^b UCB PHARMA   (Belgium)

^c KEIO UNIVERSITY   (Japan)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e NONE   (United States)

Author keywords

CT1746; matrix metalloproteinase inhibitors; MMPs; tumor growth

Indexed keywords

METALLOPROTEINASE INHIBITOR; N1 (1 CARBAMOYL 2,2 DIMETHYLPROPYL) 2 [3 (4 CHLOROPHENYL)PROPYL] N4 HYDROXYBUTANEDIAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; TUMOR GROWTH;

AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; METALLOENDOPEPTIDASES; MICE; MICE, NUDE; NEOPLASM PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 8244260609     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018461112732     Document Type: Article

References (38)

1. Liotta LA, Steeg PS and Stetler-Stevenson W, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-36.
2. Ray JM and Stetler-Stevenson WG, 1995, Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J, 14, 908-17.
3. Frisch SM, Reich R, Collier IE, Genrich LT, Martin G and Goldberg GI, 1990, Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells. Oncogene, 5, 75-83.
4. Schultz RM, Silberman S, Persky B, Bajkowski AS and Carmichael DF, 1988, Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B-16 F10 melanoma cells. Cancer Res, 48, 5539-45.
5. DeClerk YA, Perez N, Shimada H, et al. 1992, Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 52, 701-8.
6. Anderson IA, Shipp MA, Docherty AJP and Teicher BA, 1996, Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewig lung carcinoma. Cancer Res, 56, 715-8.
7. Wang X, Fu X, Brown PD, Crimmin MJ and Hoffman RM, 1994, Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res, 54, 4726-28.
8. Goldmann E, 1907, The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet, 2, 1236-40.
9. Galardy RE, Grobelny D, Foellmer HG and Fernandez, LA, 1994, Inhibition of angiogenesis by the matrix metalloproteinase inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentonyl)]-L-tryptophan methylamide. Cancer Res, 54, 4715-18.
10. Taraboletti G, Garofalo A, Bellotti D, et al. 1995, Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst, 87, 293-8.
11. Braverman AS, 1993, Chemotherapeutic failure: resistance or insensitivity. Ann Int Med, 118, 630-2.
12. Hoffman RM, 1992, Patient-like models of human cancer in mice. Curr Perspec Molec Cell Oncol, 1(B), 311-29.
13. Hoffman RM, 1994, Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models? J Cell Biochem, 56, 1-3.
14. Fu X, Guadagni F and Hoffman RM, 1992, A metastatic nude-mice model of human pancreatic cancer constructed orthotopically from histologically-intact patient specimens. Proc Natl Acad Sci, USA, 89, 5645-9.
15. Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M and Hoffman RM, 1993, Orthotopic transplantation of histologically-intact clinical specimens of stomach cancer to nude mice: correlation of metastasis sites in mouse and human, Int J Cancer, 53, 608-12.
16. Chander SK, Antoniw P, Beeley NRA, et al. 1995, An in vivo model for screening peptidomimetic inhibitors of gelatinase A. J Pharm Sci, 84, 404-9.
17. Kubota T, Shimosato Y and Nagai K, 1978, Experimental chemotherapy of carcinoma of the human stomach and colon serially transplanted in nude mice. Gann, 68, 299-309.
18. Murphy G, Willenbrock F, Ward RV, et al. 1992, The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, hut is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J. 283, 637-41.
19. Henderson B, Docherty AJP and Beeley NRA, 1990, Design of inhibitors of cartilage destruction. Drugs Future, 15, 496-508.
20. Beeley NRA, Ansell PRJ and Docherty AJP, 1994, Inhibitors of matrix metalloproteinase (MMPs). Curr Opinion Ther Patents, 4, 7-16.
21. Beckett RP, Davidson AH, Drummond AH, Huxley P and Whittaker M, 1996, Recent advances in matrix metalloproteinase inhibitor research. DDT, 1, 16-26.
22. Nagase H, Okada Y, Suzuki K, Enghild JJ and Salvesen G, 1991, Substrate specificities and activation mechanisms of the precursors of matrix metalloproteinases. Biochem Soc Trans, 19, 715-18.
23. Crabbe T, O'Connell JP, Smith BJ and Docherty AJP, 1994, Reciprocated matrix metalloproteinase activation: a process performed by interstitial collagenase and progelatinase A. Biochemistry, 33, 14419-25.
24. Tsuruo T, Yamori T, Naganuma K, Tsukagoshi S, and Sakurai Y, 1983, Characterisation of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. Cancer Res, 43, 5437-42.
25. Richman PI and Bodmer WF, 1988, Control of differentiation in human colorectal carcinoma cell lines: epithelial-mesenchymal interactions. J Pathol, 156, 197-211.
26. Wortis HH, 1971, Immunological responses of "nude" mice. Clin Exp Immunol, 8, 305-17.
27. Huning T and Bevan MJ, 1980, Specificity of cytotoxic T cells from athymic mice. J Exp Med, 152, 688-702.
28. Minato N, Reid L, Neighbour A, Bloom BR and Holland J, 1980, Interferon, NK cells and persistent virus infection. Ann NY Acad Sci, 350, 42-52.
29. Sharp AK and Colston MJ, 1984, The regulation of macrophage activity in congenitally athymic mice. Eur J Immunol, 14, 102-5.
30. Benomar A, Gerlier D and Doré JF, 1986, Interaction with host macrophages and ability of human melanoma cell lines to grow in nude mice, Int J Cancer, 38, 419.
31. Herberman RB, Nunn ME, Holden HT, Staal S and Djeu JY, 1977, Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic large T cells. Int J Cancer, 19, 555.
32. Porter JR, Beeley NRA., Boyce BA, et al. 1994, Potent and selective inhibitors of gelatinase A I. Hydroxamic acid derivatives. Bioorg Med Chem Lett, 4, 2741-6.
33. Kleinwert HD, Baker WR and Stein HH, 1993, Orally-active peptide-like molecules: a case history. Biopharmacology, 6, 36-41.
34. Goetzl EJ, Banda MJ and Leppert D, 1996, Matrix metalloproteinases in immunity. J Immunol, 156, 1-4.
35. Mahadevan V, Hart IR and Lewis GP, 1989, Factors influencing blood supply in wound granuloma quantified by a new in vivo technique. Cancer Res, 49, 415-19.
36. Schipper H, Goh CR and Wang TL, 1995, Shifting the cancer paradigm: must we kill to cure? J Clin Oncol, 13, 801-7.
37. Furr BJ and Jordan VC, 1984, The pharmacology and clinical uses of tamoxifen. Pharmacol Ther, 25, 127-205.
38. Warrell RP, Frankel SR, Miller WH, et al. 1991, Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New Engl J Med, 324, 1385-93.